GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (TSE:4536) » Definitions » Cash Flow for Dividends

Santen Pharmaceutical Co (TSE:4536) Cash Flow for Dividends : 円-12,041 Mil (TTM As of Sep. 2024)


View and export this data going back to 1964. Start your Free Trial

What is Santen Pharmaceutical Co Cash Flow for Dividends?

Santen Pharmaceutical Co's cash flow for dividends for the three months ended in Sep. 2024 was 円-71 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2024 was 円-12,041 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Santen Pharmaceutical Co's quarterly payment of dividends increased from Mar. 2024 (円-89 Mil) to Jun. 2024 (円-6,097 Mil) but then declined from Jun. 2024 (円-6,097 Mil) to Sep. 2024 (円-71 Mil).

Santen Pharmaceutical Co's annual payment of dividends increased from Mar. 2022 (円-11,994 Mil) to Mar. 2023 (円-12,607 Mil) but then declined from Mar. 2023 (円-12,607 Mil) to Mar. 2024 (円-11,881 Mil).


Santen Pharmaceutical Co Cash Flow for Dividends Historical Data

The historical data trend for Santen Pharmaceutical Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Cash Flow for Dividends Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10,379.00 -11,188.00 -11,994.00 -12,607.00 -11,881.00

Santen Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.00 -5,784.00 -89.00 -6,097.00 -71.00

Santen Pharmaceutical Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-12,041 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co Headlines

No Headlines